Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Phase III

- PMLiVE

Rigel plans job cuts in R&D restructure

Follows failure of fostamatinib disodium in rheumatoid arthritis trial

- PMLiVE

Setback for GSK as melanoma vaccine misses targets

Cancer immunotherapy disappoints in phase III

- PMLiVE

AZ’s olaparib enters phase III for ovarian cancer

Development of the drug had previously been halted in 2011

- PMLiVE

GSK melanoma therapy Tafinlar cleared in EU

Follows approvals for skin cancer drug in US, Canada and Australia

- PMLiVE

AZ launches breast cancer video portal

Pharma company partners with oncology publisher for new HCP resource

- PMLiVE

AZ adds to pipeline again with Amplimmune buy

Pharma company pays $500m via its MedImmune subsidiary for the small US biotech

- PMLiVE

AZ inks $815m deal for FibroGen anaemia drug

Deal comes as company reveals second quarter performance

- PMLiVE

AZ and BMS try again with Forxiga in the US

Pharma companies re-submit diabetes drug to the FDA for approval

China flag thumb

AstraZeneca and UCB drawn into Chinese investigations

Follows country’s clampdown on GSK bribery

- PMLiVE

Former AstraZeneca VP joins Walgreens

Mark Lelinski leaves pharma for pharmacy

- PMLiVE

AstraZeneca launches Nexium YouTube channel

New AZPurpleZone channel aimed at US patients with acid reflux disease offers symptom-relief advice and product savings

- PMLiVE

Comment: AstraZeneca’s branded approach to YouTube

Company takes the path less travelled for pharma social media initiatives

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links